| HOME >> BIOLOGY >> TECHNOLOGY |
Used As A Regular Part Of Georgetown University Hospital Arsenal Against
Chronic Wounds
PRINCETON, N.J., June 18 /PRNewswire-FirstCall/ -- Derma Sciences (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that its key product, MEDIHONEY(TM) Wound & Burn Dressing with Active Leptospermum Honey, has been used by clinicians at Georgetown University Hospital's Wound Center to save a patient's limb. The clinicians had attempted to close the 3-year old wound with other devices including very expensive biological skin substitutes and hyperbaric oxygen, but had not been successful due to the complexity of the wound. Upon initial applications of MEDIHONEY, the wound closed 90 percent in only 3 weeks.
Commenting on this particular case, CEO Ed Quilty stated, "Limb salvage
is of key concern when dealing with wound care. There are over 80,000 lower
leg amputations performed each year in the US preceded by diabetic foot
ulceration, with a very high 3-year mortality rate. The type of outcome we
see in the Georgetown case confirms what we saw from MEDIHONEY usage in
Europe before licensing the product from Comvita. Since its launch here in
the US and in Canada, two things are becoming clear; First, the product is
being adopted into the formularies of very prestigious facilities, such as
Georgetown. Second, the product is being widely used as a first-line of
defense for stalled wounds, meaning wounds that have not progressed with
standard therapy. Given that almost one-half of all chronic wounds will not
progress with standard therapy, we believe MEDIHONEY is well-positioned to
be a significant product in the field of advanced wound care." He
continued, "helping patients to save their limbs gives all the employees at
Derma Sciences incredible personal satisfaction. As is the case with most
healthcare companies, the patient always comes first. It has always been
our goal to positively impact the
'/>"/>
| SOURCE Derma Sciences Inc Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board
2. Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced
3. Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
4. Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis
5. EnzySurge, Maker of DermaStream(TM), Completes Funding Round of US$4 Million
6. Board Certified Dermatologist and President-Elect of the Dermatologic Society of Greater New York, Dr. Lance H. Brown Takes His Comprehensive Practice to East Hampton, NY
7. Derma Sciences Reports First Quarter 2008 Results
8. Anacor to Present Clinical and Preclinical Data on Topical Anti-Inflammatory Candidates, AN2728 and AN2898, at the International Investigative Dermatology 2008 Conference
9. Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R)
10. Skin & Aging Article Finds Derma Sciences MEDIHONEY(TM) Helps to Promote Healing Where Antibiotics Fail
11. DermAvance Pharmaceuticals Announces Investment by Ben Franklin Technology Partners of Southeastern Pennsylvania
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |